Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Marbofloxacin is a third-generation fluoroquinolone antibiotic used exclusively in veterinary medicine. It is a synthetic, broad-spectrum, bactericidal agent effective against a wide range of gram-negative and some gram-positive bacteria. Its primary mechanism of action involves inhibition of bacterial DNA gyrase (a type II topoisomerase), which disrupts DNA replication and transcription, leading to rapid bacterial cell death. Marbofloxacin is approved for use in dogs and cats for the treatment of infections associated with susceptible bacteria, particularly those affecting the skin, soft tissue, urinary tract (bladder and kidneys), and prostate. It may also be used off-label in other species such as birds, rabbits, reptiles, and for conditions like leishmaniasis or hemoplasmosis[1][2][5]. The drug should not be administered to growing animals due to the risk of cartilage abnormalities[6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on marbofloxacin.